Table 1.
Characteristics of the study population (n = 338 prostate cancer patients).
| Se | Zn | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Variable | Overall, n = 338 | QI 41.58–72.03 (65.06), n = 107 | QII 72.05–78.07 (75.14), n = 83 | QIII 78.08–87.63 (82.82), n = 73 | QIV (Reference) 87.96–138.27 (94.78), n = 75 | p | QI 515.70–784.83 (701.67), n = 112 | QII 785.22–863.23 (820.73), n = 80 | QIII 863.76–944.15 (906.19), n = 76 | QIV (Reference) 944.26–1339.61 (1036.22), n = 70 | p |
| Status | <0.001 | <0.001 | |||||||||
| Alive | 246 (73%) | 62 (58%) | 61 (73%) | 61 (84%) | 62 (83%) | 62 (55%) | 61 (76%) | 61 (80%) | 62 (89%) | ||
| Dead | 92 (27%) | 45 (42%) | 22 (27%) | 12 (16%) | 13 (17%) | 50 (45%) | 19 (24%) | 15 (20%) | 8 (11%) | ||
| Age | 0.025 | 0.059 | |||||||||
| ≤60 (reference) 41.00–60.00 (56.57) | 77 (23%) | 17 (16%) | 22 (27%) | 13 (18%) | 25 (33%) | 16 (14%) | 20 (25%) | 20 (26%) | 21 (30%) | ||
| >60 61.00–86.00 (68.45) | 261 (77%) | 90 (84%) | 61 (73%) | 60 (82%) | 50 (67%) | 96 (86%) | 60 (75%) | 56 (74%) | 49 (70%) | ||
| Gleason | 0.3 | 0.5 | |||||||||
| <7 | 114 (34%) | 43 (40%) | 22 (27%) | 28 (38%) | 21 (28%) | 43 (38%) | 25 (31%) | 27 (36%) | 19 (27%) | ||
| 7 | 166 (49%) | 46 (43%) | 49 (59%) | 33 (45%) | 38 (51%) | 47 (42%) | 41 (51%) | 37 (49%) | 41 (59%) | ||
| >7 | 58 (17%) | 18 (17%) | 12 (14%) | 12 (16%) | 16 (21%) | 22 (20%) | 14 (18%) | 12 (16%) | 10 (14%) | ||
| PSA | 0.2 | 0.2 | |||||||||
| <4 | 19 (5.6%) | 5 (4.7%) | 5 (6.0%) | 5 (6.8%) | 4 (5.3%) | 6 (5.4%) | 3 (3.8%) | 7 (9.2%) | 3 (4.3%) | ||
| 4–10 | 185 (55%) | 48 (45%) | 47 (57%) | 47 (64%) | 43 (57%) | 53 (47%) | 44 (55%) | 47 (62%) | 41 (59%) | ||
| >10 | 134 (40%) | 54 (50%) | 31 (37%) | 21 (29%) | 28 (37%) | 53 (47%) | 33 (41%) | 22 (29%) | 26 (37%) | ||
| Prostatectomy | 0.001 | <0.001 | |||||||||
| No | 68 (20%) | 31 (29%) | 16 (19%) | 11 (15%) | 10 (13%) | 34 (30%) | 17 (21%) | 12 (16%) | 5 (7.1%) | ||
| Yes | 250 (74%) | 63 (59%) | 64 (77%) | 60 (82%) | 63 (84%) | 65 (58%) | 60 (75%) | 62 (82%) | 63 (90%) | ||
| Missing | 20 (5.9%) | 13 (12%) | 3 (3.6%) | 2 (2.7%) | 2 (2.7%) | 13 (12%) | 3 (3.8%) | 2 (2.6%) | 2 (2.9%) | ||
| Radiotherapy | 0.092 | 0.023 | |||||||||
| No | 149 (44%) | 39 (36%) | 40 (48%) | 32 (44%) | 38 (51%) | 45 (40%) | 31 (39%) | 40 (53%) | 33 (47%) | ||
| Yes | 146 (43%) | 46 (43%) | 34 (41%) | 35 (48%) | 31 (41%) | 43 (38%) | 41 (51%) | 30 (39%) | 32 (46%) | ||
| Missing | 43 (13%) | 22 (21%) | 9 (11%) | 6 (8.2%) | 6 (8.0%) | 24 (21%) | 8 (10%) | 6 (7.9%) | 5 (7.1%) | ||
| Chemotherapy | 0.011 | 0.007 | |||||||||
| No | 257 (76%) | 68 (64%) | 66 (80%) | 57 (78%) | 66 (88%) | 75 (67%) | 61 (76%) | 62 (82%) | 59 (84%) | ||
| Yes | 20 (5.9%) | 11 (10%) | 4 (4.8%) | 4 (5.5%) | 1 (1.3%) | 4 (3.6%) | 7 (8.8%) | 6 (7.9%) | 3 (4.3%) | ||
| Missing | 61 (18%) | 28 (26%) | 13 (16%) | 12 (16%) | 8 (11%) | 33 (29%) | 12 (15%) | 8 (11%) | 8 (11%) | ||
| Hormonotherapy | 0.035 | 0.10 | |||||||||
| No | 197 (58%) | 49 (46%) | 50 (60%) | 48 (66%) | 50 (67%) | 55 (49%) | 46 (58%) | 51 (67%) | 45 (64%) | ||
| Yes | 107 (32%) | 41 (38%) | 24 (29%) | 21 (29%) | 21 (28%) | 39 (35%) | 27 (34%) | 20 (26%) | 21 (30%) | ||
| Missing | 34 (10%) | 17 (16%) | 9 (11%) | 4 (5.5%) | 4 (5.3%) | 18 (16%) | 7 (8.8%) | 5 (6.6%) | 4 (5.7%) | ||
Q—quartile; PSA—prostate specific antigen.